Cari Combs

机构：NeuroGenetic Pharmaceuticals (United States), Cognitive Research (United States)

发表论文 5 篇 · 总被引 65 次 · h-index 3

代表论文

• Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease (2023 · CNS & Neurological Disorders - Drug Targets · 被引 42)
• Tavapadon as Adjunctive Treatment for Parkinson Disease (2026 · JAMA Neurology · 被引 11)
• Fixed-Dose Tavapadon for Early Parkinson Disease (2026 · JAMA Neurology · 被引 9)
• Efficacy and Safety of Tavapadon, an Orally Administered, Once-daily, Selective D1/D5 Partial Dopamine Agonist, Adjunctive to Levodopa for Treatment of Parkinson’s Disease with Motor Fluctuations (S37.003) (2025 · Neurology · 被引 2)
• Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial (2026 · The Lancet Neurology · 被引 1)